Ask Sterling

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Companies Sectors Ask Sterling Compare

Favorites

Revenue Breakdown

Chart: Revenue Breakdown for Emergent BioSolutions. Values in USD billions. In Q2 2026: Revenue 0.234, Gross Profit 0.137, Operating Income -0.125.

Revenue Flow

Chart: Revenue Flow for Emergent BioSolutions. Q2 2026, values in USD. Revenue 144%, Gross Profit 84%, Cost of Revenue 60%, Operating Income -77%, Net Income -110%.

Balance Sheet

Chart: Balance Sheet for Emergent BioSolutions. Values in currency. In Q2 2026: Total Assets 1.117, Total Liabilities 0.775, Total Equity 0.341.

Q3 2016-Q2 2026

Cash Flow

Chart: Cash Flow for Emergent BioSolutions. Values in currency. In Q2 2026: Operating Cash Flow 0.056, Free Cash Flow 0.054, Capital Expenditures 0.002.

Q3 2016-Q2 2026

Emergent BioSolutions (EBS) - Compare | Sterling

Revenue Breakdown

Chart: Revenue Breakdown for Emergent BioSolutions. Values in USD billions. In Q2 2026: Revenue 0.234, Gross Profit 0.137, Operating Income -0.125.

Revenue Flow

Chart: Revenue Flow for Emergent BioSolutions. Q2 2026, values in USD. Revenue 144%, Gross Profit 84%, Cost of Revenue 60%, Operating Income -77%, Net Income -110%.

Balance Sheet

Chart: Balance Sheet for Emergent BioSolutions. Values in currency. In Q2 2026: Total Assets 1.117, Total Liabilities 0.775, Total Equity 0.341.

Q3 2016-Q2 2026

Cash Flow

Chart: Cash Flow for Emergent BioSolutions. Values in currency. In Q2 2026: Operating Cash Flow 0.056, Free Cash Flow 0.054, Capital Expenditures 0.002.

Q3 2016-Q2 2026